GT Biopharma (GTBP) Fundamentals 2026 — Revenue Analysis | SniperIQ
GT Biopharma (GTBP) is a US-listed Healthcare company in Biotechnology with a market capitalization of $4M, trading at $0.34 on the NASDAQ. This SniperIQ fundamentals page covers GT Biopharma's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is GT Biopharma's market cap?
GT Biopharma (GTBP) has a market capitalization of approximately $4M, trading at $0.34 on the NASDAQ. Market cap moves with the live share price.
What is GT Biopharma's P/E ratio?
GT Biopharma's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is GT Biopharma?
GT Biopharma runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does GT Biopharma pay a dividend?
GT Biopharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is GT Biopharma financially healthy?
GT Biopharma carries a debt-to-equity ratio of 0.00x and a current ratio of 3.69x, with a market beta of 0.84. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is GT Biopharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For GT Biopharma (GTBP) the key facts are: market cap $4M, 52-week range 0.261-2.29. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track GT Biopharma's full fundamentals live
Get GT Biopharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.